Previous Close | 154.95 |
Open | 155.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 155.00 - 155.00 |
52 Week Range | 135.40 - 174.75 |
Volume | |
Avg. Volume | 8 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Investing.com -- Shares in Merck KGaA (ETR:MRCG) slumped by more than 10% on Tuesday after the drugmaker announced that it had discontinued a Phase III study evaluating its treatment for patients with head and neck cancer.
Most readers would already know that Merck KGaA's (ETR:MRK) stock increased by 4.5% over the past three months. Given...
Merck KGaA (MKGAF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.